| 1.13 -0.17 (-13.08%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.44 |
| Resists | First : | 1.78 | Second : | 2.09 |
| Pivot price | 1.09  |
|||
| Supports | First : | 0.84 | Second : | 0.26 |
| MAs | MA(5) : | 1.39  |
MA(20) : | 1.02 |
| MA(100) : | 0.74 |
MA(250) : | 0.82 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 67.3 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 1.78 | Low : | 0.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PDSB ] has closed below upper band by 46.8%. Bollinger Bands are 149.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.27 |
| Low: | 1.09 - 1.1 | 1.1 - 1.11 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Thu, 15 Oct 2026
H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Wed, 14 Oct 2026
PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 14 Oct 2026
PDS Biotechnology Corporation (PDSB) Stock Price | Live Quotes & Charts | NASDAQ - Timothy Sykes
Wed, 14 Oct 2026
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Tue, 13 Oct 2026
PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story - StocksToTrade
Tue, 13 Oct 2026
PDSB Jumps As JAMA Data And Nant Capital Deal Shift Outlook - Timothy Sykes
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 19.1 (%) |
| Held by Institutions | 10.7 (%) |
| Shares Short | 2,770 (K) |
| Shares Short P.Month | 2,350 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -70.6 % |
| Return on Equity (ttm) | -544 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -1.77 |
| PEG Ratio | 0 |
| Price to Book value | -18.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|